Ivermectin Sigillata

Ivermectin, the active ingredient in Ivermectin Sigillata, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for systemic use. It is employed to treat a range of parasitic infections in humans, including onchocerciasis, strongyloidiasis, scabies, and lice infestations.

GNH USA supplies Ivermectin Sigillata as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Ivermectin is an anthelmintic that targets parasitic helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and helps prevent ocular and skin disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents hyperinfection syndrome. - Scabies: eradicates Sarcoptes scabiei mites, relieving intense itching and skin lesions. - Pediculosis: kills head lice and nits, controlling infestation. - Other helminth infections: treats various nematode infections as indicated by clinical guidelines.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Diarrhea: loose stools during treatment. - Abdominal pain: cramping or discomfort. - Headache: mild to moderate. - Pruritus: itching at the site of parasite death.

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic toxicity: seizures, ataxia, or altered mental status. - Anaphylaxis: acute allergic reaction with airway compromise. - Vision disturbances: blurred vision or optic neuritis. - Severe hypotension: marked drop in blood pressure.

Before prescribing Ivermectin, clinicians should consider several safety measures. - Hypersensitivity: avoid use in patients with known allergy to ivermectin or excipients. - Hepatic impairment: assess liver function; dose adjustment may be required in severe disease. - Central nervous system disorders: use cautiously in patients with a history of seizures or neurodegenerative conditions. - Concomitant CYP3A4 inhibitors: monitor for increased drug exposure when strong inhibitors are co‑administered. - Pregnancy and breastfeeding: evaluate risk‑benefit ratio; limited data are available. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivermectin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): can raise systemic exposure and risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect; monitor INR. - Other antiparasitics (e.g., benzimidazoles): may increase gastrointestinal irritation. - Immunosuppressants: monitor for altered infection risk or drug levels.